SCHEMBL23327992

SCHEMBL23327992

O=C(NCc1cccnc1N1CCOCC1)c1cnnc(-c2ccc(OCC(F)(F)F)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 8/20 0.59
SCN2A Q99250 7/20 0.59
SCN5A Q14524 2/20 0.44
KCNH2 Q12809 1/20 0.44
PDE4B Q07343 1/20 0.43
HDAC1 Q13547 3/20 0.40
KDM1A O60341 2/20 0.40
MCHR1 Q99705 2/20 0.40
ABL1 P00519 3/20 0.39
POLB P06746 1/20 0.38
SCN9A Q15858 1/20 0.38
HTR2C P28335 1/20 0.38
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23327995 0.91 SCN10A (0.71) SCN10ASCN2APDE4BHDAC1KDM1A
SCHEMBL23327661 0.88 SCN10A (0.57) SCN10ASCN2APDE4BHDAC1KDM1A
SCHEMBL23327988 0.88 SCN10A (0.57) SCN10ASCN2APDE4BHDAC1KDM1A
SCHEMBL29195333 0.87 SCN10A (0.56) SCN10ASCN2APDE4BHDAC1KDM1A
SCHEMBL23328010 0.87 SCN10A (0.57) SCN10ASCN2AHDAC1KDM1AMCHR1
SCHEMBL23344751 0.86 SCN10A (0.62) SCN10ASCN2AHDAC1KDM1AMCHR1
SCHEMBL23327910 0.86 SCN10A (0.75) SCN10ASCN2ASCN5AKCNH2HDAC1
SCHEMBL23344685 0.84 SCN10A (0.60) SCN10ASCN2AHDAC1KDM1AMCHR1
SCHEMBL23327907 0.84 SCN10A (0.66) SCN10ASCN2AHDAC1KDM1AMCHR1
SCHEMBL23327653 0.82 SCN10A (0.53) SCN10ASCN2ASCN5AKCNH2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP claimed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US claimed
CN-112689629-B For inhibiting Nav1.8 Pyridazine Compounds 利伯研究所公司 2024-04-23 CN claimed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US claimed
CN-112689629-A For inhibiting Nav1.8 pyridazine Compounds 利伯研究所公司 2021-04-20 CN claimed
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP disclosed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US disclosed
CN-112689629-B For inhibiting Nav1.8 Pyridazine Compounds 利伯研究所公司 2024-04-23 CN disclosed
EP-3820860-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 EP disclosed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US disclosed
CN-112689629-A For inhibiting Nav1.8 pyridazine Compounds 利伯研究所公司 2021-04-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN5A, SCN2A SCN10A 8/4885SCN2A 3/4885SCN5A 2/4885
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 SCN8A, SCN5A, SCN2A SCN10A 8/4885SCN2A 3/4885SCN5A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.